Atara Biotherapeutics Inc at Citi BioPharma Conference Transcript
Hello, everyone. Thank you for joining us for our cell therapy autoimmune panel. I'm Sam Semenkow, one of the biotech analysts here at Citi. I'm joined with my colleague, Yigal Nochomovitz, on the end.
It's my pleasure to have with us today, Gwen Binder, she is a President of Science & Tech at Cabaletta; Pascal Touchon, CEO and President of Atara Bio; and Kevin Xie, CEO and President of Gracell -- CFO. I'm sorry, CFO. I got mixed up.
Yes. Well, thank you for all joining us today for what I hope will be a lively panel.
So just to kick it off, perhaps we could just go down the line. If you could all give a very brief, like 1 to 2, summary of your company and what you're working on.
Yes, thanks. Really, a pleasure to be here. Cabaletta Bio is a clinical stage biotechnology company. We're focused -- since -- we were found in 2018 and since the beginning, we've been focused on developing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
